Schistosomiasis is an immunopathogenic disease characterized by egg granuloma and fibrosis. The hepatic fibrosis of schistosomiasis is caused by the coordinated action of local immune cells, liver-resident cells and related cytokines around the eggs of the liver. B-cell-activating factor (BAFF), expressed in many cells, is an essential factor for promoting the survival, differentiation, and maturation of cells. The overexpression of BAFF is closely related to many autoimmune diseases and fibrosis, but has not been reported to play a role in liver fibrosis caused by schistosomiasis. In the study, we found that, during () infection in mice, the level of BAFF and its receptor BAFF-R progressively increased, then decreased with the extension of infection time, which was consistent with the progression of hepatic granuloma and fibrosis. Anti-BAFF treatment attenuated the histopathological damage in the liver of infected mice. The average areas of individual granulomas and liver fibrosis in anti-BAFF treatment mice were significantly lower than those in control mice, respectively. Anti-BAFF treatment increased the IL-10, decreased IL-4, IL-6, IL-17A, TGF-β, and downregulated the antibody level against antigens. These results suggested that BAFF acts a strong player in the immunopathology of schistosomiasis. Anti-BAFF treatment may influence Th2 and Th17 responses, and reduce the inflammatory reaction and fibrosis of schistosomiasis liver egg granuloma. It is suggested that BAFF might be a prospective target for the development of new methods to treat schistosomiasis liver fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302281 | PMC |
| http://dx.doi.org/10.3390/pathogens12060793 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE.
Nat Immunol
January 2025
Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.
Severe acute respiratory syndrome coronavirus 2 mRNA vaccination has reduced effectiveness in certain immunocompromised individuals. However, the cellular mechanisms underlying these defects, as well as the contribution of disease-induced cellular abnormalities, remain largely unexplored. In this study, we conducted a comprehensive serological and cellular analysis of patients with autoimmune systemic lupus erythematosus (SLE) who received the Wuhan-Hu-1 monovalent mRNA coronavirus disease 2019 vaccine.
View Article and Find Full Text PDFB cell targeting in IgA nephropathy.
Nephrology (Carlton)
September 2024
Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Article Synopsis
- The multi-hit theory explains that IgA nephropathy (IgAN) starts with galactose-deficient IgA1 (GdIgA1), leading to chronic inflammation and progressive kidney damage due to complement pathway activation and increased pressure within the glomeruli.
- New treatments are emerging that target different stages of IgAN's pathophysiology, including drugs that regulate complement, block endothelin receptors, and inhibit glucose reabsorption in kidneys. Promising clinical trials are underway for therapies aimed at reducing GdIgA1 production by targeting specific B cells.
- The production of nephrit
Current status of BAFF targeting immunotherapy in B-cell neoplasm.
Int J Clin Oncol
November 2024
Laboratory of Molecular Immunology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
B-cell activating factor belonging to the TNF family (BAFF), also known as B-lymphocyte stimulator (BLyS), plays a crucial role in B-cell development. It has multiple receptors, including BCMA, TACI, and BAFF-R, with diverse roles in different cell types. BAFF induces B-cell proliferation and immunoglobulin secretion, and acts as a survival factor for immature, naive, and activated B cells.
View Article and Find Full Text PDFNovel treatments for immune thrombocytopenia: targeting platelet autoantibodies.
Expert Rev Hematol
September 2024
Department of Medicine, McMaster University, Hamilton, Canada.
Article Synopsis
- Immune thrombocytopenia (ITP) is an autoimmune disorder leading to low platelet counts and increased bleeding risk, with autoantibodies targeting platelet glycoproteins causing their destruction.
- New treatments, such as Neonatal Fc receptor (FcRn) antagonists and Syk inhibitors, aim to reduce harmful autoantibodies and improve patient outcomes by interfering with their clearance and production.
- The review emphasizes the significance of understanding these pathogenic mechanisms and highlights the promise of targeted therapies in managing ITP, despite the challenge of detecting autoantibodies.
Unveiling the dynamics of B lymphocytes in systemic lupus erythematosus patients treated with belimumab through longitudinal single-cell RNA sequencing.
Rheumatology (Oxford)
July 2024
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Seoul, South Korea.
Article Synopsis
- The study aims to understand how B cells respond to targeted therapy (belimumab) in patients with systemic lupus erythematosus (SLE) using single-cell transcriptome data.
- Researchers performed single-cell RNA sequencing on blood samples from four SLE patients at various time points during treatment, identifying distinct changes in B cell populations over time.
- Findings reveal notable dynamics, such as declines in certain B cell types and downregulated activation pathways, suggesting new insights into the immunological effects of anti-BAFF therapy and the potential for immune profiling to predict treatment responses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!